Page 93 - 《中国药房》2022年21期

·药物与临床·

扶正养血膏干预化疗致骨髓抑制的临床疗效及安全性研究 Δ

#
＊
陈 琳 ，程宗琦，姚 鑫，毛叶勤（苏州大学附属第一医院药学部，江苏 苏州 215006）
中图分类号 R730.6；R285 文献标志码 A 文章编号 1001-0408（2022）21-2643-04
DOI 10.6039/j.issn.1001-0408.2022.21.15

摘 要 目的 观察扶正养血膏干预化疗致骨髓抑制的临床疗效及安全性。方法 回顾性收集2018年1月－2020年12月于我院
首次确诊为恶性肿瘤拟行“紫杉醇联合铂类”化疗方案的患者资料。患者共200例，根据有无使用扶正养血膏分为试验组和对照
组，每组各100例。对照组常规化疗；试验组在首次化疗开始后联合口服扶正养血膏，直至该次化疗周期结束。比较2组患者首次
出现骨髓抑制的时间、骨髓抑制发生率、补救用药情况和生活质量等指标。结果 首次化疗后，对照组患者的白细胞计数、中性粒
细胞计数、血小板和血红蛋白水平均显著低于首次化疗前（P＜0.05）；试验组患者的白细胞计数和中性粒细胞计数均显著低于首
次化疗前（P＜0.05），但显著高于对照组（P＜0.05）。试验组患者骨髓抑制发生率（39.00%）显著低于对照组（63.00%）（P＜0.05）。
试验组首次出现骨髓抑制的时间（化疗后第11.0天）滞后于对照组（化疗后第6.7天）。首次化疗周期内，对照组使用升白细胞药物
的患者例数（28例）显著多于试验组（11例）（P＜0.05）。首次化疗后，2组患者的KPS评分均显著低于首次化疗前（P＜0.05），但试
验组患者KPS评分显著高于对照组（P＜0.05）。首次化疗后，2组患者神疲乏力、食少纳呆、头晕心悸、恶心呕吐、自汗盗汗评分均
显著高于首次化疗前，但试验组患者的自汗盗汗评分显著低于对照组（P＜0.05）。2组患者首次化疗前后谷丙转氨酶、谷草转氨
酶、尿素和肌酐水平均在正常范围内。结论 扶正养血膏能有效降低化疗致骨髓抑制的发生率，延缓出现骨髓抑制的时间，减少临
床补救性升白细胞药/升血小板药的使用量，降低中医证候评分，提高患者生活质量。
关键词 扶正养血膏；骨髓抑制；恶性肿瘤；化疗；中医证候评分

Study on clinical efficacy and safety of Fuzheng yangxue ointment on myelosuppression induced by
chemotherapy
CHEN Lin，CHENG Zongqi，YAO Xin，MAO Yeqin（Dept. of Pharmacy，the First Affiliated Hospital of
Soochow University，Jiangsu Suzhou 215006，China）
ABSTRACT OBJECTIVE To observe the clinical efficacy and safety of Fuzheng yangxue ointment in the intervention of

chemotherapy-induced myelosuppression. METHODS The data of 200 patients were collected retrospectively，who were diagnosed
as malignant tumors in our hospital for the first time from January 2018 to December 2020 and were to receive the chemotherapy
scheme of“paclitaxel combined with platinum”. According to whether Fuzheng yangxue ointment was used or not，they were
divided into trial group and control group，with 100 cases in each group. The control group received routine chemotherapy，and the
trial group took Fuzheng yangxue ointment orally after the first chemotherapy until the end of this chemotherapy cycle. The time of
the first occurrence of myelosuppression，the incidence of myelosuppression，the use of rescue drugs，quality of life and other
indicators were compared between 2 groups. RESULTS After the first chemotherapy，white blood cell count，neutrophil count，the
levels of platelet and hemoglobin in control group were significantly lower than those before the first chemotherapy（P＜0.05）. The
white blood cell count and neutrophil count of patients in the trial group were significantly lower than those before the first
chemotherapy（P＜0.05），but significantly higher than those in the control group（P＜0.05）. The incidence of myelosuppression in
the trial group （39.00%） was significantly lower than that （63.00%） in control group （P＜0.05）. The occurrence time of
myelosuppression for the first time in the trial group（11.0th day after chemotherapy）was later than that in the control group（6.7th
day after chemotherapy）. During the first chemotherapy cycle，the number of patients in the control group（28 cases）using drugs
for increasing white cells was significantly higher than that in the trial group（11 cases）（P＜0.05）. After the first chemotherapy，
KPS scores of patients in both groups were significantly lower
Δ 基金项目“十二五”国家临床重点专科建设项目（No.国卫办医 than those before the first chemotherapy（P＜0.05），but KPS
函〔2018〕292号）；苏州市科技发展计划项目（No.SYSD2020175）
scores of patients in the trial group were significantly higher
＊第一作者 副主任中药师，硕士。研究方向：中药临床药学。电
话：0512-67780241。E-mail：chenliner198506@163.com than those in the control group （P＜0.05）. After the first
# 通信作者 副主任中药师。研究方向：中药制剂。电话：0512- chemotherapy， the scores of fatigue， anorexia， dizziness，
67780241。E-mail：13913159302@163.com palpitation，nausea and vomiting，and spontaneous sweating

中国药房 2022年第33卷第21期 China Pharmacy 2022 Vol. 33 No. 21 ·2643·